Post‐diagnostic multivitamin supplement use and colorectal cancer survival: A prospective cohort study

Ming‐ming He,Kai Wang,Chun‐Han Lo,Yiwen Zhang,Georgios Polychronidis,Markus D. Knudsen,Rong Zhong,Yuan Ma,Kana Wu,Andrew T. Chan,Edward L. Giovannucci,Shuji Ogino,Kimmie Ng,Jeffrey A. Meyerhardt,Mingyang Song
DOI: https://doi.org/10.1002/cncr.35234
IF: 6.9209
2024-02-08
Cancer
Abstract:Background Use of multivitamin supplements has been associated with lower incidence of colorectal cancer (CRC). However, its influence on CRC survival remains unknown. Methods Among 2424 patients with stage I–III CRC who provided detailed information about multivitamin supplements in the Nurses' Health Study and Health Professionals Follow‐up Study, the authors calculated multivariable hazard ratios (HRs) of multivitamin supplements for all‐cause and CRC‐specific mortality according to post‐diagnostic use and dose of multivitamin supplements. Results During a median follow‐up of 11 years, the authors documented 1512 deaths, among which 343 were of CRC. Compared to non‐uses, post‐diagnostic users of multivitamin supplements at a dose of 3–5 tablets/week had lower CRC‐specific mortality (HR, 0.55; 95% confidence interval [CI], 0.36–0.83, p = .005), and post‐diagnostic users at doses of 3–5 and 6–9 tablets/week had lower all‐cause mortality (HR, 0.81; 95% CI, 0.67–0.99, p = .04; HR, 0.79; 95% CI, 0.70–0.88), p
oncology
What problem does this paper attempt to address?